Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.13−0.24 (-3.26%)
Close on Nov 17, 2026Market cap $382.38MP/E –Yield –
Avalo Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Avalo Therapeutics's price to sales ratio was 118.3× on Apr 30, 2025, against 7.1× a year earlier. Over the last 5 years it ranged from 0.1× to 190.2×, with a median of 15.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 118.3× | +30.5 |
| 2024 | Dec 31, 2024 | 87.7× | +84.5 |
| 2023 | Dec 29, 2023 | 3.2× | +0.5 |
| 2022 | Dec 30, 2022 | 2.7× | −25.9 |
| 2021 | Dec 31, 2021 | 28.6× | −5.6 |
| 2020 | Dec 31, 2020 | 34.2× | +12.9 |
| 2019 | Dec 31, 2019 | 21.3× | +12.7 |
| 2018 | Dec 31, 2018 | 8.6× | +5.4 |
| 2017 | Dec 29, 2017 | 3.2× | – |
See a number that looks wrong?